Candel Therapeutics (CADL) Income from Continuing Operations (2020 - 2025)
Candel Therapeutics recorded quarterly Income from Continuing Operations of 16066000.0 in Q4 2025, down 29.41% quarter-over-quarter from 12415000.0 in Q3 2025, and down 94.95% year-over-year from 318269004.81 in Q4 2024.
Candel Therapeutics' Income from Continuing Operations history runs 6 years deep, the most recent figure standing at 16066000.0 for Q4 2025.
- In Q4 2025, Income from Continuing Operations fell 94.95% year-over-year to 16066000.0; the TTM figure through Dec 2025 stood at 46470000.0 (down 35.19% YoY), while the FY2025 annual figure was 46470000.0, down 35.19% from the prior year.
- Income from Continuing Operations came in at 16066000.0 for Q4 2025 at Candel Therapeutics, down from 12415000.0 in the prior quarter.
- In the past five years, Income from Continuing Operations ranged from a high of 4669000.0 in Q1 2021 to a low of 16066000.0 in Q4 2025.
- A 5-year average of 9037000.0 and a median of 9018000.0 in 2023 frame the typical range for Income from Continuing Operations.
- Across the five-year window, Income from Continuing Operations sank 197.01% in 2021 and rose 22.08% in 2024, its largest moves.
- Candel Therapeutics' Income from Continuing Operations stood at 7751000.0 in 2021, then decreased by 1.6% to 7875000.0 in 2022, then slumped by 34.3% to 10576000.0 in 2023, then grew by 22.08% to 8241000.0 in 2024, then slumped by 94.95% to 16066000.0 in 2025.
- According to Business Quant data, Income from Continuing Operations over the past three periods registered 16066000.0, 12415000.0, and 10487000.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | -2.99 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | -8.40 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -14.46 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 1.03 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | -3.40 Mn |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 727.20 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 205.99 Mn |
| 10 | Candel Therapeutics | 449.62 Mn | 449.62 Mn | - | -16.07 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -16.07 Mn |
| Sep 30, 2025 | -12.42 Mn |
| Jun 30, 2025 | -10.49 Mn |
| Mar 31, 2025 | -7.50 Mn |
| Dec 31, 2024 | -8.24 Mn |
| Sep 30, 2024 | -9.01 Mn |
| Jun 30, 2024 | -8.90 Mn |
| Mar 31, 2024 | -8.23 Mn |
| Dec 31, 2023 | -10.58 Mn |
| Sep 30, 2023 | -9.03 Mn |
| Jun 30, 2023 | -9.77 Mn |
| Mar 31, 2023 | -9.53 Mn |
| Dec 31, 2022 | -7.88 Mn |
| Sep 30, 2022 | -9.06 Mn |
| Jun 30, 2022 | -9.12 Mn |
| Mar 31, 2022 | -9.16 Mn |
| Dec 31, 2021 | -7.75 Mn |
| Sep 30, 2021 | -8.04 Mn |
| Jun 30, 2021 | -5.32 Mn |
| Mar 31, 2021 | -4.67 Mn |
| Dec 31, 2020 | -6.08 Mn |
| Sep 30, 2020 | -2.71 Mn |
| Jun 30, 2020 | -2.53 Mn |